Other matters addressed in the bill include
grants related to health disparities and for centers for public health preparedness;
collection and dissemination of public health data (e.g., genomic sequencing of pathogens);
workforce programs for public health and related fields;
the safety and availability of the blood supply;
research concerning viruses and other pathogens with pandemic potential, vaccines and other medical countermeasures, and the long-term health effects of COVID-19;
biosafety and security related to biological agents and toxins;
national security, privacy and information security, and foreign influence in biomedical research;
the administration of the Strategic National Stockpile; and
domestic manufacturing of medical countermeasures.
The bill also modifies the regulation of medical products with a particular focus on expediting the development and approval of medical countermeasures. Additional areas of focus include strengthening medical product supply chains and supporting innovation in, for example, clinical trial designs.